As predators go, cone snails are slow moving and lack the typical fighting parts. They’ve made up for it by producing a vast array of fast-acting toxins that target the nervous systems of prey. A new study reveals that some cone snails add a weaponized form of insulin to the venom cocktail they use to disable fish.
More efficient medical treatments could be developed thanks to a new method for triggering the rearrangement of chemical particles. The new method, developed at the Univ. of Warwick, uses two “parent” nanoparticles that are designed to interact only when in proximity to each other and trigger the release of drug molecules contained within both.
A regime of anti-HIV drugs has the potential to protect against infection in the first place. But real life can interfere; the effectiveness of this prophylactic approach declines if the medications aren’t taken as prescribed. HIV researchers hope a new compound, known as cabotegravir, could make dosing easier for some because the drug would be administered by injection once every three months.
Chemists have made a significant advancement to directly functionalize C-H bonds in natural products by selectively installing new carbon-carbon bonds into highly complex alkaloids and nitrogen-containing drug molecules. C-H functionalization is a much more streamlined process than traditional organic chemistry, holding the potential to greatly reduce the time and number of steps needed to create derivatives of natural products.
In the midst of a worrisome flu season, health officials are pushing doctors to prescribe antiviral medicines. The Centers for Disease Control and Prevention on Friday sent a new alert to doctors, advising prompt use of Tamiflu and other antivirals for hospitalized flu patients and those at higher risk for complications like pneumonia.
For years, pathogens’ resistance to antibiotics has put them one step ahead of researchers, which is causing a public health crisis, according to Northeastern Univ. Distinguished Prof. Kim Lewis. But in new research, Lewis and his colleagues present a newly discovered antibiotic that eliminates pathogens without encountering any detectable resistance.
A major barrier to finding a cure for HIV/AIDS is the presence of latent HIV in the cells of chronically infected individuals. But a team of Yale and Johns Hopkins researchers may have pinpointed a strategy for eliminating the residual virus. Despite treatment with antiretroviral therapy, HIV persists in patients in a latent reservoir.
Researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis.
Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. A panel of FDA experts ruled that the company's version of Neupogen is highly similar to Amgen's original blockbuster biotech drug, which is used to boost blood cells that help cancer patients fight off infections.
An international team of researchers has developed a drug delivery technique that utilizes graphene strips as “flying carpets” to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.
New research findings point toward a class of compounds that could be effective in combating infections caused by enterovirus D68, which has stricken children with serious respiratory infections in the U.S. and elsewhere. The researchers used x-ray crystallography to learn the precise structure of the original strain of EV-D68 on its own and when bound to an anti-viral compound called "pleconaril."
With drug-resistant bacteria on the rise, even common infections that were easily controlled for decades are proving trickier to treat with standard antibiotics. New drugs are desperately needed, but so are ways to maximize the effective lifespan of these drugs. To accomplish that, Duke Univ. researchers used software they developed to predict a constantly evolving infectious bacterium's countermoves to one of these new drugs ahead of time.
A company that is developing new anti-viral drugs hopes it will have a cure for Ebola, which is still in the research phase, put on the fast track for development in the fight against the disease. NanoViricides, whose headquarters are in West Haven, opened its research and development lab in July. The company, with a net worth of $250 million, employs more than 20 and expects to double that in the next two years.
The tequila sure looks real, so do the beer taps. Inside the hospital at the National Institutes of Health, researchers are testing a possible new treatment to help heavy drinkers cut back, using a replica of a fully stocked bar. The idea: Sitting in the dimly lit bar-laboratory should cue the volunteers' brains to crave a drink, and help determine if the experimental pill counters that urge.
The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years. FDA drug approvals are considered a barometer of industry innovation and the federal government's efficiency in reviewing new therapies. Last year's total was the most since the all-time high of 53 drugs approved in 1996.
Researchers at Swinburne University of Technology have discovered an instability in gold nanoparticles that is critical for their application in future technology. Gold nanorods are important building blocks for future applications in solar cells, cancer therapy and optical circuitry.
Scientists often test drugs in mice. Now some cancer patients are doing the same—with the hope of curing their own disease. They are paying a private lab to breed mice that carry bits of their own tumors so treatments can be tried first on the customized rodents. The idea is to see which drugs might work best on a specific person's cancer.
As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.
Nearly half of all U.S. adults, nearly 117 million individuals, are living with one or more chronic health conditions. This has become the age of chronic disease, and achieving better outcomes depends on developing tools for research and clinical care that efficiently and accurately address the complex diseases we face today.
Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing Plasmodium falciparum parasite. This finding provides public health officials around the world with a way to look for pockets of emerging resistance and potentially eliminate them before they spread.
Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.
Penicillin, the wonder drug discovered in 1928, works in ways that are still mysterious almost a century later. One of the oldest and most widely used antibiotics, it attacks enzymes that build the bacterial cell wall, a mesh that surrounds the bacterial membrane and gives the cells their integrity and shape. Once that wall is breached, bacteria die, allowing us to recover from infection.
Take two poisonous mushrooms, and call me in the morning. While no doctor would ever write this prescription, toxic fungi may hold the secrets to tackling deadly diseases. A team of Michigan State Univ. scientists has discovered an enzyme that is the key to the lethal potency of poisonous mushrooms.
Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don’t get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating asthma by targeting the trigger—the allergen—before it can spark an attack. They describe their new compound, which they tested on rats, in the Journal of Medicinal Chemistry.
The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS. The Oxford Univ.-led study also indicates that people infected by HIV are likely to progress to AIDS more slowly—in other words the virus becomes less “virulent”—because of widespread access to antiretroviral therapy (ART).